COMMUNIQUÉS West-GlobeNewswire
-
Blood Cancer Patients and Their Supporters Cycle Across Iceland to Raise Funds and Awareness for Multiple Myeloma and the International Myeloma Foundation’s Research
16/04/2026 -
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
16/04/2026 -
Helsinn appoints Giacomo Braglia to the Board of Directors
16/04/2026 -
Wellcome Leap Announces $2 Million Prize in $50 Million Quantum for Bio Challenge Program
16/04/2026 -
Nanox.ARC X Digital Advanced 3D imaging built for access and powered by innovation Wins 2026 Red Dot Award for Product Design
16/04/2026 -
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
16/04/2026 -
Kane Biotech Presents revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference
16/04/2026 -
Philips receives FDA 510(k) clearance for Verida, the world’s first AI-powered detector-based spectral CT*, advancing diagnostic precision across clinical applications
16/04/2026 -
Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
16/04/2026 -
Hemp Hop’s First 420 Deals in Houston, TX - Buy 3 Get 1 Free 2026
16/04/2026 -
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
16/04/2026 -
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
16/04/2026 -
VTAK Definitive Agreement to Acquire 100% of Fly Flyte Inc. Obtains Shareholder Approval
16/04/2026 -
Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors
16/04/2026 -
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
16/04/2026 -
Nearly 4 in 10 women are missing vaginal bacteria linked to fertility
16/04/2026 -
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
16/04/2026 -
Roquette réalise avec succès son émission obligataire hybride, pour un montant de 600 millions d'euros
16/04/2026 -
Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure
16/04/2026
Pages